JPRN-jRCT1080222004未知Unknown
Post-marketing surveillance of eribulin mesilate (Investigation of the clinical safety and effectiveness in patients with inoperable or recurrent breast cancer)
适应症
试验速览
- 阶段
- Unknown
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Inoperable breast cancer
- •Recurrent breast cancer
排除标准
- •Corresponding to contraindication of eribulin mesilate
- •Not applicable to indications of eribulin mesilate
- •Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs
研究者
相似试验
已完成
不适用
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)Inoperable or Recurrent Breast CancerNCT01463891Eisai Co., Ltd.963
Unknown
不适用
The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary LesionsCardiovascular DiseasesCoronary DiseaseCoronary RestenosisHeart DiseasesCoronary StenosisArterial Occlusive DiseasesVascular DiseasesMyocardial IschemiaCoronary Artery DiseaseArteriosclerosisNCT01915420Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.42
已完成
不适用
Post-marketing surveillance for refractory uveoretinitis associated with Behcet's disease under Remicade treatmentBehcet's diseaseJPRN-UMIN000027733Mitsubishi Tanabe Pharma Corporation100
已完成
4 期
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast CancerBreast NeoplasmsNCT03583944Eisai Inc.200
已完成
不适用
Post marketing surveillance of EdirolOsteoporosisJPRN-UMIN000018333Chugai Pharmaceutical Co.Ltd3,000